HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Wellness Dietary Supplements Legislation

NZ Industry Slams Gov For “Stalling” On Supps Bill

  • News

Executive Summary

New Zealand's industry association for natural health products accuses the country's government of stalling after it pushed back new legislation in favor of yet more consultation. 

You may also be interested in...



Protect IP To Encourage Switching In Australia, Urges ASMI

The Australian Self Medication Industry (ASMI) is calling for IP protection for successful prescription-to-OTC reclassification applications to encourage switching in Australia. 

Supplements Industry Under Threat In Australia With 'Made In' Claim Restrictions

Claiming a dietary supplement is 'Made in Australia' has become much harder, threatening the long term viability of a thriving industry, warns Complementary Medicines Australia.

Health Marketing Round-Up: January 2019

New OTC products and marketing campaigns in Germany, Australia and the UK.

Table

View full table

Topics

Tags:
Wellness Dietary Supplements Legislation
Latest Headlines

Prestige Expands UK Eye Care Range In Response To Consumer Demand

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD

Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories

See All
UsernamePublicRestriction

Register

RS148536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By